Answers are grounded in this paper and cite their sources.
The results on the use of gammaG-immunoglobulin to Rh factor for the prevention of active immunization of Rh-negative mothers at risk appear most promising. One hundred and seven mothers in the clinical trial have been followed for periods of about 6 months to 1(1/2)12 years after delivery. Of these, 48 were treated mothers who received 5 ml gammaG-immunoglobulin to Rh, and 59 were untreated mothers. Of the 48 treated mothers none are actively immunized; seven of the 59 control mothers have become actively immunized to Rh.
No takes yet. Share an insight, caveat, or question.
Freda et al. (1966) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: